You are here

Article info

Article menu
Immunotherapy biomarkers
Original research
eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma

Authors

  • Xisha Chen Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, ChinaHunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha, China PubMed articlesGoogle scholar articles
  • Kuansong Wang Department of Pathology, Xiangya hospital and Department of Pathology, School of Basic Medicine, Central South University, Changsha, China PubMed articlesGoogle scholar articles
  • Shilong Jiang Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China PubMed articlesGoogle scholar articles
  • Hongyin Sun Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China PubMed articlesGoogle scholar articles
  • Xuanling Che Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China PubMed articlesGoogle scholar articles
  • Minghui Zhang Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China PubMed articlesGoogle scholar articles
  • Jiaying He Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China PubMed articlesGoogle scholar articles
  • Ying Wen Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China PubMed articlesGoogle scholar articles
  • Mengting Liao Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China PubMed articlesGoogle scholar articles
  • Xiangling Li Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, ChinaHunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha, China PubMed articlesGoogle scholar articles
  • Xiaoming Zhou Department of Pharmacy, School of Medicine, Hunan Normal University, Changsha, China PubMed articlesGoogle scholar articles
  • Jianxun Song Department of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, Bryan, Texas, USA PubMed articlesGoogle scholar articles
  • Xingcong Ren Department of Cancer Biology and Toxicology, Department of Pharmacology, College of Medicine, Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA PubMed articlesGoogle scholar articles
  • Wenjun Yi Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China PubMed articlesGoogle scholar articles
  • Jinming Yang Department of Cancer Biology and Toxicology, Department of Pharmacology, College of Medicine, Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA PubMed articlesGoogle scholar articles
  • Xiang Chen Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China PubMed articlesGoogle scholar articles
  • Mingzhu Yin Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China PubMed articlesGoogle scholar articles
  • Yan Cheng Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, ChinaHunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha, China PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Yan Cheng, Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China; yancheng{at}csu.edu.cn; Professor Mingzhu Yin, Department of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China; yinmingzhu2008{at}126.com; Dr Xiang Chen, Department of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China; chenxiangck{at}126.com
View Full Text

Citation

Chen X, Wang K, Jiang S, et al
eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma
Journal for ImmunoTherapy of Cancer 2022;10:e004026. doi: 10.1136/jitc-2021-004026

Publication history

  • Accepted March 3, 2022
  • First published March 28, 2022.
Online issue publication 
October 18, 2023

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.